PTGX
Protagonist Therapeutics, IncCompany Information
- Company Name
- Protagonist Therapeutics, Inc
- CIK
- CIK0001377121
- Category
- Large accelerated filer
- Ticker: Exchange
- PTGX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- PTGX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-10
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 433,326
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 73,123,715
- Shares outstanding
- 65,935,769
- Ownership
- 110.90%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 5.10%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 420 | 194 | 128 | 114 | 169 | 140 | 97 | 131 | 356 | 173 | 187 | 231 | ||||||
| Marketable Securities Current | 362 | 354 | 439 | 462 | 402 | 435 | 322 | 338 | 208 | 150 | 155 | 90 | ||||||
| Contract With Customer Asset Gross Current | - | - | - | - | - | - | 165 | - | 0 | 300 | 10 | - | ||||||
| Receivables Long Term Contracts Or Programs | 13 | 54 | 0 | 1 | - | - | 165 | - | - | - | - | - | ||||||
| Contract With Customer Asset Net Current | 3 | - | - | - | 23 | 23 | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 8 | 12 | 10 | 10 | 9 | 9 | 8 | 8 | 7 | 5 | 4 | 4 | ||||||
| Assets Current | 807 | 613 | 578 | 586 | 603 | 606 | 592 | 477 | 571 | 628 | 356 | 325 | ||||||
| Marketable Securities Noncurrent | 67 | 73 | 79 | 103 | 102 | 124 | 140 | 115 | 31 | - | - | 2 | ||||||
| Property Plant And Equipment Net | 3 | 4 | 4 | 4 | 4 | 4 | 3 | 2 | 2 | 1 | 1 | 1 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 7 | 7 | 8 | 8 | 9 | 9 | 9 | 10 | 10 | 0 | 1 | 2 | ||||||
| Other Assets Noncurrent | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets | 886 | 697 | 668 | 702 | 718 | 742 | 745 | 604 | 615 | 629 | 358 | 330 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 8 | 5 | 6 | 3 | 3 | 2 | 3 | 4 | 4 | 1 | 1 | ||||||
| Other Accounts Payable And Accrued Liabilities | 22 | 17 | 28 | 23 | 15 | 12 | 24 | 21 | 15 | 16 | 19 | 25 | ||||||
| Deferred Income Current | 10 | 6 | 10 | 14 | 15 | 17 | 19 | 20 | 20 | 16 | - | - | ||||||
| Accrued Income Taxes Current | - | - | - | - | - | 2 | 3 | 1 | 3 | 3 | - | - | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | - | 0 | 1 | 2 | ||||||
| Liabilities Current | 37 | 35 | 45 | 45 | 36 | 35 | 47 | 45 | 42 | 40 | 21 | 28 | ||||||
| Deferred Revenue Noncurrent | - | - | - | 3 | 5 | 8 | 12 | 17 | 21 | 29 | - | - | ||||||
| Operating Lease Liability Noncurrent | 7 | 7 | 8 | 9 | 9 | 10 | 10 | 11 | 11 | - | - | - | ||||||
| Liabilities | 44 | 42 | 53 | 56 | 50 | 53 | 69 | 72 | 73 | 69 | 21 | 28 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,146 | 1,123 | 1,085 | 1,071 | 1,055 | 1,041 | 1,016 | 1,003 | 981 | 969 | 952 | 945 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 1 | 1 | -0 | 0 | -0 | 1 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -304 | -467 | -471 | -426 | -387 | -352 | -341 | -472 | -439 | -408 | -616 | -643 | ||||||
| Stockholders Equity | 842 | 655 | 615 | 645 | 668 | 689 | 675 | 532 | 541 | 560 | 337 | 302 | ||||||
| Liabilities And Stockholders Equity | 886 | 697 | 668 | 702 | 718 | 742 | 745 | 604 | 615 | 629 | 358 | 330 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 90 | 90 | 90 | ||||||
| Common Stock Shares Issued | 65 | 64 | 63 | 62 | 62 | 62 | 61 | 60 | 59 | 59 | 58 | 58 | ||||||
| Shares Outstanding | 65 | 64 | 63 | 62 | 62 | 62 | 61 | 60 | 59 | 59 | 58 | 58 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialProtagonist Therapeutics, Inc (PTGX) — SEC Financial Statements & Analysis
Protagonist Therapeutics, Inc (PTGX) is a pharmaceutical preparations company, incorporated in DE. Protagonist Therapeutics, Inc trades on Nasdaq as: PTGX. Protagonist Therapeutics, Inc (PTGX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Protagonist Therapeutics, Inc carries a market cap of $8.08B, a P/E ratio of 97.49x, a P/B ratio of 9.60x, a P/S ratio of 28.66x, an enterprise value of $7.66B, and an EV/EBITDA multiple of 127.95x. On profitability, it posts an operating margin of 20.69%, a net margin of 29.40%, a Return on Equity (ROE) of 10.98%, a Return on Assets (ROA) of 10.34%, and a Return on Invested Capital (ROIC) of 11.88%. Per share, it reports EPS of $1.26, diluted EPS of $1.17, free cash flow per share of $1.98, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 34.81% year-over-year, net income growth of 59.32% year-over-year, and EPS growth of 53.46% year-over-year. On the balance sheet, it maintains a current ratio of 21.71x, a quick ratio of 21.50x, working capital of $769.97M, a debt-to-equity ratio of 0.05x, a debt ratio of 0.05, free cash flow of $130.58M (TTM), and net debt of $-420.37M. Figures sourced from SEC EDGAR.
- Market Cap
- $8.08B
- P/E TTM
- 97.49x
- EPS TTM
- $1.26
- P/B TTM
- 9.60x
- ROE TTM
- 10.98%
- ROA TTM
- 10.34%
- Debt To Equity
- 0.05x
- Free Cash Flow TTM
- $130.58M
- Net Revenue TTM Growth 1Y
- 34.81%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Protagonist Therapeutics, Inc in?
Protagonist Therapeutics, Inc (PTGX) operates in the Pharmaceutical Preparations industry.
What exchange does PTGX trade on?
Protagonist Therapeutics, Inc (PTGX) trades on the Nasdaq.
Where is Protagonist Therapeutics, Inc incorporated?
Protagonist Therapeutics, Inc is incorporated in DE.
When was Protagonist Therapeutics, Inc (PTGX)'s most recent SEC filing?
Protagonist Therapeutics, Inc (PTGX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is PTGX's market cap?
Protagonist Therapeutics, Inc (PTGX) has a market capitalization of $8.08B as of 2026-06-30.
What is PTGX's P/E ratio?
Protagonist Therapeutics, Inc (PTGX)'s trailing twelve month P/E ratio is 97.49x as of 2026-06-30.
What is PTGX's EPS (earnings per share)?
Protagonist Therapeutics, Inc (PTGX)'s trailing twelve month EPS is $1.26 as of 2026-06-30.
What is PTGX's ROE (return on equity)?
Protagonist Therapeutics, Inc (PTGX)'s trailing twelve month Return on Equity (ROE) is 10.98% as of 2026-06-30.
What is PTGX's ROA (return on assets)?
Protagonist Therapeutics, Inc (PTGX)'s trailing twelve month Return on Assets (ROA) is 10.34% as of 2026-06-30.
What is PTGX's ROIC (return on invested capital)?
Protagonist Therapeutics, Inc (PTGX)'s trailing twelve month Return on Invested Capital (ROIC) is 11.88% as of 2026-06-30.
What is PTGX's EV/EBITDA?
Protagonist Therapeutics, Inc (PTGX)'s trailing twelve month EV/EBITDA is 127.95x as of 2026-06-30.